Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis

Sorrel E Wolowacz, David A Cameron, Helen C Tate, Adrian Bagust

Research output: Contribution to journalArticlepeer-review

Abstract

To estimate the cost effectiveness of TAC (docetaxel, doxorubicin, and cyclophosphamide) compared with FAC (fluorouracil, doxorubicin, and cyclophosphamide) when administered as adjuvant therapy to women with node-positive early breast cancer in the United Kingdom (UK), both with and without primary prophylaxis with granulocyte colony-stimulating factor (G-CSF).
Original languageEnglish
Pages (from-to)925-33
Number of pages9
JournalJournal of Clinical Oncology
Volume26
Issue number6
DOIs
Publication statusPublished - 2008

Keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Axilla
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Cost-Benefit Analysis
  • Cyclophosphamide
  • Decision Trees
  • Disease-Free Survival
  • Doxorubicin
  • Female
  • Fluorouracil
  • Granulocyte Colony-Stimulating Factor
  • Great Britain
  • Humans
  • Kaplan-Meier Estimate
  • Lymph Nodes
  • Lymphatic Metastasis
  • Markov Chains
  • Neoplasm Staging
  • Neutropenia
  • Protective Agents
  • Quality-Adjusted Life Years
  • Taxoids

Fingerprint

Dive into the research topics of 'Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis'. Together they form a unique fingerprint.

Cite this